Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)

NCT04639986 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

331

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

DRUG: Sacituzumab Govitecan-hziy
DRUG: Eribulin Mesylate Injection
DRUG: Capecitabine Oral Product
DRUG: Gemcitabine Injection
DRUG: Vinorelbine injection

Sponsor

Gilead Sciences